Najnowsze artykuły: EU Reaffirms Rejection of Rare Sleep Disorder DrugHetlioz (tasimelteon) will not gain an expanded EU indication for Smith-Magenis syndrome after the European Medicines Agency (EMA) upheld its earlier rejection following reexamination. The rejected ...